Aims: To evaluate the short-term safety and efficacy of a single intravitreal bevacizumab injection in patients with polypoidal choroidal vasculopathy (PCV). Methods: The records of patients treated with intravitreal bevacizumab for PCV were retrospectively reviewed. All patients were evaluated by complete ophthalmic examination, optical coherence tomography and fluorescein and indocyanine green angiography. Changes in visual acuity and central retinal thickness (CRT) over 3 months were the main outcome measures. Results: Nineteen eyes of 18 patients were included. No serious ocular or systemic adverse events were observed. The median baseline visual acuity and CRT were 20/100 and 230 μm, respectively. After 1 month, there was no significant improvement in median visual acuity (20/80+1; p = 0.055), but median CRT had decreased significantly (160 μm; p < 0.001). After 3 months (data available for 17 eyes), both median visual acuity (20/63–2; p = 0.001) and CRT (190 μm; p = 0.007) showed significant improvements over baseline values. Conclusions: Intravitreal bevacizumab therapy for PCV was well tolerated over the 3-month follow-up period. Short-term results are promising, but further studies are necessary to evaluate long-term efficacy.

Keywords:
Polypoidal choroidal vasculopathy, Choroidal neovascularization, Vascular endothelial growth factor, Bevacizumab, Intravitreal injection
1.
Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA: The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 1997;115:478–485.
2.
Schneider U, Gelisken F, Kreissig I: Indocyanine green angiography and idiopathic polypoidal choroidal vasculopathy. Br J Ophthalmol 1998;82:98–99.
3.
Okubo A, Sameshima M, Uemura A, Kanda S, Ohba N: Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study. Br J Ophthalmol 2002;86:1093–1098.
4.
Moorthy RS, Lyon AT, Rabb MF, Spaide RF, Yannuzzi LA, Jampol LM: Idiopathic polypoidal choroidal vasculopathy of the macula. Ophthalmology 1998;105:1380–1385.
5.
Yuzawa M, Mori R, Haruyama M: A study of laser photocoagulation for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2003;47:379–384.
6.
Nishijima K, Takahashi M, Akita J, Katsuta H, Tanemura M, Aikawa H, Mandai M, Takagi H, Kiryu J, Honda Y: Laser photocoagulation of indocyanine green angiographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 2004;137:770–773.
7.
Vedantham V, Kolluru C, Ramasamy K: Treatment of polypoidal choroidal vasculopathy with transpupillary thermotherapy: an interventional case report. Eye 2005;19:915–917.
8.
Okubo A, Ito M, Kamisasanuki T, Sakamoto T: Visual improvement following trans-Tenon’s retrobulbar triamcinolone acetonide infusion for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 2005;243:837–839.
9.
Terasaki H, Miyake Y, Suzuki T, Nakamura M, Nagasaka T: Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation. Br J Ophthalmol 2002;86:321–327.
10.
Shiraga F, Matsuo T, Yokoe S, Takasu I, Okanouchi T, Ohtsuki H, Grossniklaus HE: Surgical treatment of submacular hemorrhage associated with idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 1999;128:147–154.
11.
Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, Wong TH: Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 2004;111:1576–1584.
12.
Ojima Y, Tsujikawa A, Otani A, Hirami Y, Aikawa H, Yoshimura N: Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy. Am J Ophthalmol 2006;141:958–960.
13.
Adamis AP, Shima DT: The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111–118.
14.
Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391–400.
15.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
16.
Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM: Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536–544.
17.
Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383–390.
18.
Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G: Short-term safety and efficacy of intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Retina 2006;26:495–511.
19.
Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA: Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005;89:1368–1370.
20.
Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN: Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1–9.
21.
Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU: Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569–4578.
22.
Aisenbrey S, Ziemssen F, Volker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU: Intravitreal bevacizumab (avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:941–948.
23.
Han DP: Intravitreal human immune globulin in a rabbit model of Staphylococcus aureus toxin-mediated endophthalmitis: a potential adjunct in the treatment of endophthalmitis. Trans Am Ophthalmol Soc 2004;102:305–320.
24.
Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS: Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006;141:456–462.
25.
Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M: Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 2004;88:809–815.
26.
Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U: Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814–2823.
27.
Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A: Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (avastin). Retina 2006;26:262–269.
28.
Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H, Fukushima I, Takahashi K, Matsumura M: Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002;133:639–648.
29.
Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, Tano Y: Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:70–73.
30.
Ghajarnia M, Kurup S, Eller A: The therapeutic effects of intravitreal bevacizumab in a patient with recalcitrant idiopathic polypoidal choroidal vasculopathy. Semin Ophthalmol 2007;22:127–131.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.